Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study https://t.co/h4LtQIvIie これか?
RT @NickPowellLab: This is an important question. The infliximab data are encouraging in terms of response, but poor quality studies (small…
This is an important question. The infliximab data are encouraging in terms of response, but poor quality studies (small numbers and prone to reporting bias) - complicate this issue.
@sang_hyoung @MondayNightIBD @DrJohnKisiel @DrJNaidoo @DavidFaleckMD @gulleyj1 @alexshoushtari @ptandonGI @NickPowellLab 5/ My preference goes for Vedo over IFX for ICI colitis - Effective, les concern about risk of infection, or TB reactivation in this po
@mjayoushe @MondayNightIBD @AkbarWaljee @ibddoctor @EdwardLoftus2 Both biologics can be used to treat ICI- colitis, I have a preference for Vedo , our study https://t.co/micMzLAjqK
As I’ve read this before- seems to be faster for ICPI colitis than traditional IBD
@IBDimmunology @MondayNightIBD @DavidFaleckMD In our experience, response to Vedo is rapid for #Immunotherapy induced enterocolitis , w often drastic improvement of BM within few days after the 1st dose https://t.co/micMzLAjqK
RT @DavidFaleckMD: @SchairerIBDMD @drkeithsiau @MondayNightIBD @sloan_kettering @Gut_BMJ In irColitis, the largest published report of Vedo…
RT @DavidFaleckMD: @SchairerIBDMD @drkeithsiau @MondayNightIBD @sloan_kettering @Gut_BMJ In irColitis, the largest published report of Vedo…
@SchairerIBDMD @drkeithsiau @MondayNightIBD @sloan_kettering @Gut_BMJ In irColitis, the largest published report of Vedo (n=28) reported median time to response of 5 days https://t.co/KJqEw0m2Il We use IFX>>VDZ @sloan_kettering, but in my own experie
@DCharabaty @DavidFaleckMD @MondayNightIBD @sloan_kettering Exactly! Interesting point to highlight from your study that pts failing a trial of IFX before vedolizumab are at ⬆️ risk of prolonged streroid Rx and less effective response to vedolizumab 👍🏼 htt
@DavidFaleckMD @MondayNightIBD @sloan_kettering 2/ would you check IFX drug level and ATI and if “off” then go for Vedolizumab ? We had good experience using Vedo for #Immunotherapy induced Colitis in pts with CI or not responding to IFX #JITC https://t.co
RT @alexshoushtari: @VUMChealth For severe irAEs, steroids like prednisone at 1mg/kg daily are often mainstay of therapy. Other pathways ca…
@FunchainMD @alexshoushtari @CCalabreseDO @FredWuPA @JosephHabibi_MD @Pradnya_PatilMD 1/ TY for sharing ! Great tweetorial ! As GI, My main experience w irAEs has been w enterocolitis, usually responsive to IFX or Vedo (& you cite our paper w the MDAnd
RT @alexshoushtari: @VUMChealth For severe irAEs, steroids like prednisone at 1mg/kg daily are often mainstay of therapy. Other pathways ca…
RT @alexshoushtari: @VUMChealth For severe irAEs, steroids like prednisone at 1mg/kg daily are often mainstay of therapy. Other pathways ca…
RT @alexshoushtari: @VUMChealth For severe irAEs, steroids like prednisone at 1mg/kg daily are often mainstay of therapy. Other pathways ca…
@VUMChealth For severe irAEs, steroids like prednisone at 1mg/kg daily are often mainstay of therapy. Other pathways can be targeted if needed, e.g. for colitis. Active area of research: TNF-a, e.g. infliximab https://t.co/5QtnqFQ1PU Integrin a4b7, vedoli
RT @DCharabaty: @NickPowellLab @stevenbollipo Check out our studies on using #Vedolizumab or #infliximab to treat immune checkpoint inhibit…
RT @DCharabaty: @NickPowellLab @stevenbollipo Check out our studies on using #Vedolizumab or #infliximab to treat immune checkpoint inhibit…
Yes, great work Aline. You guys and Mimi are really driving this important field forward.
@NickPowellLab @stevenbollipo Check out our studies on using #Vedolizumab or #infliximab to treat immune checkpoint inhibitor #colitis #immunotherapy https://t.co/micMzLRUii and https://t.co/cAhEsyEpXU
@j0nnymac1 @MDAndersonNews @HopkinsMedicine @sibleyonline @ClevelandClinic @bcmhouston TY @j0nnymac1 for your comments ! 1- In our practice, Vedo is becoming the preferred biologic for #immunotherapy colitis https://t.co/micMzLAjqK 2- Its best to do EGD/
@margamajem @Ivana_Sullivan
RT @iTOXreport: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study @sitcan…
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study @sitcancer https://t.co/O4q9sIhY41
RT @sitcancer: #JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center…
#JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study https://t.co/zpGWo07yIW https://t.co/6kj1P7mMV4
#JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study https://t.co/zpGWo07yIW https://t.co/KtStJwGQT1
RT @sitcancer: #JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center…
#JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study https://t.co/zpGWo07yIW https://t.co/3DbpcOOSHc
RT @DCharabaty: Great discussion on management of an #IBD mimic: immune checkpoint inhibitor colitis @Marylandibddoc @sonia_friedman @Imede…
RT @DCharabaty: Great discussion on management of an #IBD mimic: immune checkpoint inhibitor colitis @Marylandibddoc @sonia_friedman @Imede…
Great discussion on management of an #IBD mimic: immune checkpoint inhibitor colitis @Marylandibddoc @sonia_friedman @ImedexCME #AIBD2018 Shared our experience using vedolizumab https://t.co/micMzLAjqK
RT @IBD_Afzali: Use of vedolizumab for checkpoint inhibitor-induced colitis. @DCharabaty 👏 https://t.co/bETuWEFVkC
RT @DCharabaty: Our study with @MDAndersonNews colleagues is out: #vedolizumab #Entyvio is effective and safe in treating immune checkpoint…
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study @sitcancer https://t.co/O4q9sIhY41
RT @DCharabaty: Our study with @MDAndersonNews colleagues is out: #vedolizumab #Entyvio is effective and safe in treating immune checkpoint…
RT @dianalfranco: @MRegueiroMD vedolizumab for checkpoint inhibitor enterocolitis https://t.co/eKinfPrSoz
RT @dianalfranco: @MRegueiroMD vedolizumab for checkpoint inhibitor enterocolitis https://t.co/eKinfPrSoz
@MRegueiroMD vedolizumab for checkpoint inhibitor enterocolitis
Use of vedolizumab for checkpoint inhibitor-induced colitis. @DCharabaty 👏
RT @DCharabaty: Our study with @MDAndersonNews colleagues is out: #vedolizumab #Entyvio is effective and safe in treating immune checkpoint…
Our study with @MDAndersonNews colleagues is out: #vedolizumab #Entyvio is effective and safe in treating immune checkpoint inhibitor enterocolitis @JJGastroMD @BioMedCentral https://t.co/micMzLAjqK
RT @sitcancer: New #JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-ce…
RT @sitcancer: New #JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-ce…
New #JITC Research: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study https://t.co/zpGWo07yIW https://t.co/Eni51VIj0I